Table 1.

Clinical profile of all enrolled patients

	Total	Hydroxychloroquine	CDK4/6 inhibitor
	(n = 13)	(n = 8)	(n = 5)
Age, median (range), years	60 (50, 77)	58.5 (50, 77)	60 (51, 72)
Sex, male	9 (69.2%)	6 (75.0%)	3 (60.0%)
Smoking history, yes	3 (23.1%)	2 (25.0%)	1 (20.0%)
Drinking history, yes	4 (30.8%)	3 (37.5%)	1 (20.0%)
Diabetes, yes	3 (23.1%)	1 (12.5%)	2 (40.0%)
Performance status
0–1	4 (30.8%)	4 (50.0%)	0 (0%)
2	9 (69.2%)	4 (50.0%)	5 (100%)
CA19-9, median (range), U/ml	840 (1, 20500)	1290 (13, 9480)	65 (1, 20500)
TNM stage IV	13 (100%)	8 (100%)	5 (100%)
Liver metastasis	11 (84.6%)	7 (87.5%)	4 (80.0%)
Multiple metastases	5 (38.5%)	2 (25.0%)	3 (60.0%)
Line of therapy
3	4 (30.8%)	3 (37.5%)	1 (20.0%)
4	5 (38.5%)	2 (25.0%)	3 (60.0%)
5–7	4 (30.8%)	3 (37.5%)	1 (20.0%)
KRAS mutation
G12D	6 (46.2%)	4 (50.0%)	2 (40.0%)
G12V	7 (53.8%)	4 (50.0%)	3 (60.0%)
Cyclin gene mutation
CDKN2A	4 (30.8%)	0 (0%)	4 (80.0%)
CDKN1B	1 (7.7%)	0 (0%)	1 (20.0%)
None	8 (61.5%)	8 (100%)	0 (0%)